We used site-directed mutagenesis to generate mutations in the -10 region of the lac P2 promoter. The mutations were crossed onto lambda bacteriopahage carrying the lac regulatory elements and an intact lacZ gene, and the effects of the various mutations were determined in vivo and in vitro. Two of four mutations had effects on the start point of the P2-directed transcript and had very little effect on lac expression. Another mutation, which abolishes P2 promoter activity in vitro, also had very little effect on lac expression in vivo. We suggest that the P2 promoter plays little or no role in the activation of the P1 promoter by catabolite activator protein in complex with cyclic AMP.
Analyses of the regulatory sequences controlling lac operon expression have revealed several mechanisms which affect the level of transcription. One mechanism involves the binding of lac repressor to the operator sequence to prevent transcription from the lac promoter. Another mechanism controlling lac expression is the activation of transcription from the lac promoter by catabolite activator protein (CAP) in complex with cyclic AMP (cAMP). The DNA sequences which are known to be intimately involved in transcription initiation and CAM-cAMP stimulation of the lac promoter have been fairly well described by mutational analyses and protection studies (2, 17, 18) . While lac repressor is thought to act by preventing RNA polymerase from interacting with the promoter, it is unknown how CAP-cAMP stimulates the transcription process. CAP-cAMP could interact with RNA polymerase directly or through the DNA to effect transcription stimulation.
Malan and McClure (7) have proposed that overlapping RNA polymerase-binding sites in the lac promoter region are involved in CAP-cAMP stimulation of transcription. One of these RNA polymerase-binding sites, P1 (5, 6, 13, 14) , directs the synthesis of the mRNA from which lac proteins are translated in vivo. An overlapping RNA polymerasebinding site, P2, directs the synthesis of RNA in vitro but does not appear to be active in directing RNA synthesis in vivo (8, 14) . The role that the P2 promoter plays in lac expression in vivo is unknown. In vitro analyses suggest that in the absence of CAP-cAMP, RNA polymerase binding at the P2 site is very strong and thus may prevent accessibility of the P1 promoter. CAP-cAMP prevents P2 binding and in this way might facilitate RNA polymerase binding to the P1 promoter (7, 14) . This model predicts that mutations which abolish P2 activity without affecting P1 activity should cause the P1 promoter to become CAP-cAMP independent. Deletion mutations of the P2 promoter region described by Yu and Reznikoff (20) suggest that decreasing P2 activity does not affect the CAP-cAMP-independent activity of the P1 promoter.
Alternatively, it has been suggested that the P2 binding site might act in a positive manner, to facilitate the activity of the P1 promoter by increasing the local concentration of RNA polymerase near the productive or P1 promoter (20) . If this model were correct, mutations which abolish P2 activity would decrease the extent of CAP-cAMP stimulation of lac. The deletions described by Yu and Reznikoff (20) cannot test this possibility, since either they affect the CAP-cAMP binding site as well as the P2 site or they affect the spacing between the CAP-cAMP binding site at P1.
We show here that point mutations which abolish or change the in vitro properties of the P2 promoter, without significantly altering the in vivo properties of the P1 promoter, have very little effect on CAP-cAMP-dependent or -independent lac expression. M13mp8 phage were grown on strain RZ1032 (F' lysA/dut ung thi-l relA spoTI supE), and single-stranded phage were isolated. Phage genomes grown on this strain contain deoxyuridine in the place of deoxythymidine, which results in very poor efficiency of transformation into wild-type cells. The single-stranded DNA was isolated (see DNA sequencing) and used as the template for mutagenesis.
MATERUILS AND METHODS
The oligonucleotides were obtained from the Biotechnology Center, Madison, Wis. The oligonucleotide used to generate mutations at position -30 had the sequence 5'AGCATAAANTGTAAAG3' (where N is a mixture of A, C, and T and corresponds to the -30 position in the lac sequence). The oligonucleotide used to mutate position -29 had the sequence 5'AGCATAANGTGTAAAG3' (where N is a mixture of G, C, and T and corresponds to the -29 position).
Before use in mutagenesis, the oligonucleotides were purified on a 20% polyacrylamide sequencing gel (9) Approximately 100 blue patches were visible on a confluent growth of Lac-phage. Blue plaques were purified by being streaked several times.
CSH26 and CSH26A cya were lysogenized with the recombinant phage as described by Yu Table 1 are averages of at least three separate experiments.
In vitro transcription. DNA templates used for in vitro transcription were prepared by digesting M13 replicative form (RF) DNA with PvuII and EcoRI and eluting a 176-base-pair fragment from 5% polyacrylamide gel (9) . In vitro transcription assays were performed by using the buffer described by Majors (6) Exonuclease HI protection. Protection of the promoter DNA from exonuclease III digestion was performed as described by Peterson and Reznikoff (14) . The probe for these experiments was a 406-base-pair AvaI-EcoRI fragment (isolated from M13mp8 RF DNA or its mutant derivatives) 5' end labeled at the AvaI site. This was purified from a 5% polyacrylamide gel. Reactions were carried out under the same conditions as those for in vitro transcription reactions. Between 0.1 and 0.5 pmol of DNA was incubated with 1.5 pmol of RNA polymerase for 10 min. Heparin was added, and 1 min later, 25 U of exonuclease III was added. After 15 min, the reaction was terminated with 20 plI of stop solution and 100 ,A of cold ethanol. Samples were prepared for electrophoresis as described for transcription experiments and electrophoresed through a 5% polyacrylamide-7 M urea gel.
Si nuclease mapping. RNA was isolated from CSH26 containing prophage with either the wild-type lac regulatory region or the various mutant derivatives. The RNA was prepared as described by Peterson and Reznikoff (13) . A 176-base-pair PvuII-EcoRI fragment 5 ' end labeled at the EcoRI site was purified from M13mp8 RF DNA and used as a probe. S1 nuclease mapping was performed as described by Peterson and Reznikoff (13) with about 10,000 cpm of end-labeled probe and 50 ,ug of RNA.
RESULTS
Oligonucleotide mutagenesis. We sought to generate mutations in the lac regulatory region which would affect the P2 RNA polymerase-binding site without affecting the P1 site. While it is difficult to define which base pairs of the P1 site are not required for its activity, we assumed that the most important elements of the P1 and P2 promoters are those in the conserved hexanucleotide sequences centered at posi- the start point of lac transcription (Fig. 1 ). Mutations at these positions were generated by oligonucleotide-directed mutagenesis.
To maximize the number of mutagenic events, we used the M13 mutagenesis procedure described by Kunkle Four different point mutations in the lac promoter were isolated and are shown in Fig. 1 . To assay the effect of these mutations on lac expression in vivo, the mutations were crossed onto a lambda phage containing the lac regulatory region and lacZ, X lysogens were constructed, and P-galactosidase activities were measured. Table 1 lists P-galactosidase levels in cya+ and Acya backgrounds. The mutants all have slightly increased lac expression in the wild-type background. In the absence of CAP-cAMP (in the Acya background), the mutations cause a greater increase in P-galactosidase activity. (To be certain that the X prophages contain the mutations in the lac region, the mutations were crossed back onto M13mp8. These recombinants were sequenced and contain the appropriate mutations [data not shown].)
In vitro transcription. On the basis of models of promoter sequence structure, the mutations discussed above would be expected to affect the activity of the P2 promoter while leaving the P1 promoter unaffected. Since the only assays for activity of the P2 promoter are in vitro assays, we sought to determine the P2 activity of these mutants by in vitro transcription experiments. Figure 2 shows the products of runoff transcription from wild-type and mutant lac promoters. The P1 and P2 transcripts were identified by size and by the effect of CAP-cAMP addition to the transcription reaction mixture. CAP-cAMP is known to repress P2 activity and stimulate P1 activity in vitro (7, 15) . The wild-type template (as well as the mutant templates) appears to generate multiple transcripts for both P1 and P2 promoters (Fig. 2, lanes 1  and 6) .
The (Fig. 3) . Peterson and Reznikoff (14) showed that RNA polymerase protects the P1 promoter from exonuclease III digestion up to position + 19 and the P2 promoter up to M I 2 3 position -5. In the absence of CAP-cAMP, RNA polymerase binds predominantly at the P2 site in the wild-type lac regulatory region. Figure 3 , lane 1, shows the exonuclease III protection pattern on the wild-type template. The prominent band is approximately 350 bases long, which corresponds to a decrease of the probe by 57 bases. This is about position -5 in the lac region and is probably the boundary of the P2 binding site. A less prominent band of about 370 bases is seen also, and this most probably is the boundary of the P1 binding site. Lanes 2, 4, and 5 show that mutants -29A, -30A, and -30T, respectively, have an exonuclease III protection pattern which suggests that RNA polymerase is able to bind in the region of the P2 binding site. Interestingly, although several of these mutants seem to bind in the vicinity of the P2 site, they appear to generate complexes with slightly different downstream boundaries. Lane 2 shows that RNA polymerase binds to -29A template at many sites; lane 4 shows that the binding of RNA polymerase to -30A template is similar to its binding to wild-type template; and lane 5 shows that binding of RNA polymerase to the -30T template generates a protected fragment which is smaller than the fragment corresponding to the P2 boundary. (These alternative binding patterns and the start points of transcription from the mutant templates will be discussed below.) Lane 3, however, shows that RNA polymera,se does not appear to bind to the -29C template near the P2 site in this assay, because the only protected fragment which is seen corresponds to the P1 site. This is the same mutation which seems to abolish P2 transcription activity in vitro (Fig. 2) .
Sl mapping. All of the mutations discussed above either alter the pattern of P2 transcription in vitro or abolish this activity. These mutations, however, affect ,3-galactosidase expression very little. We were curious to know whether the start point for transcription of the in vivo 3-galactosidase mRNA was altered by these mutations. The start point was verified in vivo by Si mapping. RNA was purified from strains carrying the X prophages with either the wild-type lac regulatory region or the mutant regions. This RNA was hybridized to an end-labeled DNA probe, and the hybrids were digested with Si nuclease; the products are shown in Fig. 4 . Lanes 2, 3, 4, and 5 show that the Si-resistant fragments generated, when RNA from the strains with mutated lac regions is used, are the same size as when the wild-type strain is used. While the quantity of RNA used in each experiment was approximately the same, there seem to be some differences in the amount of protected fragment. We believe that this is due to a variability in recovery of the products. Lane 6 shows that when RNA from a strain carrying the same prophage, but which encodes a severe down mutation in the lac promoter, is used, no protected fragment of the same size appears.
DISCUSSION
The results of these studies of mutants in the lac regulatory region strongly support the idea that the P2 RNA polymerase-binding site is not involved in CAP-cAMP stimulation of lac expression in vivo. Several of the mutations modestly alter the P2 activity in vitro (-29A, -30A, and -30T). One mutation (-29C) appears to abolish all P2 activity (in vitro transcription and binding reactions). Because the -29C mutation causes the greatest decrease in P2 activity, this mutation is the best test for the possible involvement of the P2 promoter in CAP-cAMP stimulation of lac expression. Lambda lysogens carrying this mutation, however, have a slight increase (15% in cya+ and 30% in cya-) in 3-galactosidase activity. This incrase may reflect a slight effect of the P2 promoter on P1 activity. However, because all of the mutations described here slightly enhance ,3-galactosidase expression and have P2 promoter activity in vitro, it is more likely that the increases seen with all of the mutations described here (including -29C) are merely due to increasing the activity of the P1 promoter directly.
The various mutations, however, had surprising effects on the in vitro activities of the P2 promoter. A T residue at position -7 (the furthest-downstream T of the conserved -10 region) is thought to be the most conserved base among E. coli promoter sequences (3) . Mutations at position -29 described here are at this conserved position of the P2 promoter. This position relative to the P1 promoter is not conserved. One would expect that changing this base to any other would reduce P2 activity because this base is so highly conserved among E. coli promoter sequences. Changing this T to a C does reduce P2 activity, as expected. However, changing this T residue to an A (-29A) does not affect P2 as predicted. Rather, it appears to alter the family of start points for P2 transcription (Fig. 2, lane 2) . In addition to a transcriptional start at -22, the -29A template generates longer transcripts corresponding to positions -36 and -31. The start point for transcription from the P2 promoter is also altered when the C at position -30 is mutated to a T (Fig. 2,  lane 5) . The -30T template generates transcripts which correspond to positions -34 and -36. When the -30C residue is mutated to the conserved residue A (canonical sequence TATAAT), there is no apparent change in P2 activity either in quantity or in the family of start points (Fig.  2, lane 4) . The wild-type template generates two major start points corresponding to positions -22 (the P2 start point) and -26.
Changes in the start points may be due to recognition of an alternative promoter by RNA polymerase on these mutant templates. The exonuclease III protection experiments were designed to examine this model. RNA polymerase has an altered binding pattern on mutant templates (Fig. 3) . One would expect that a mutant template which generates a longer transcript (-29A) would cause the boundary of RNA polymerase binding to be further upstream. Instead, the binding pattern of RNA polymerase on the -29A template is much more diffuse than on the wild-type template, as if the enzyme could now make open complexes at many different sites in the vicinity of the lacP2 region (Fig. 3, lane 2) . The -29C mutation, however, abolishes the interaction of the enzyme near the P2 site, as expected (lane 3). On the -30T template (lane 5), the majority of RNA polymerase molecules appear to interact with the DNA at a site which is further upstream than the wild-type P2 site (or further away from the +1 position). Intuitively, one would expect that such an interaction would produce a longer transcript from the new "P2" site. The majority of transcripts seen from this template are actually smaller than the binding data would suggest. This discrepancy is not understood.
One would expect that the altered binding of RNA polymerase on these mutated templates would be due to the recognition of different -10 and -35 regions relative to the wild-type template. We have examined the DNA sequence of the mutated P2 promter regions but cannot locate new -10 and -35 sequences which would be consistent with the transcription and binding experiments. We cannot explain this result, except to suggest that the P2 promoter is not characteristic of productive E. coli promoters because one cannot find conditions to verify its activity in vivo. The mutations described here were designed to reduce or abolish P2 promoter activity. We were surprised to find that with the exception of -29C, our mutations had little effect on P2 activity in vitro. One interpretation of these results is that we were incorrect in our assumption that the sequence at positions -29 and -30 are critical to P2 promoter activity.
It is possible that we have not yet discovered the conditions which would allow expression from the P2 promoter in vivo. If such conditions exist, the mutations described here may be useful in studying such a phenomenon. Our results strongly suggest that the P2 site is not involved in catabolite activation of the lac operon by CAP-cAMP. Another possibility, as Meiklejohn and Gralla (10) suggest, is that the function of the P2 promoter has been lost during the evolution of a CAP-cAMP activation system for lac operon control.
